10
Jul
2023
Tag: clinical trials
12
Jun
2023
Bionest
New Moves to Enhance Diversity in Clinical Trials
Despite efforts to increase diversity in clinical trials, many groups often remain significantly under-represented.
3
Apr
2023
Bionest
The Growth of the Metaverse into Life Sciences and Health Care
Augmented reality, VR & other aspects of the metaverse are beginning to impact healthcare, from disability & elder care to hospital triage, surgical training, clinical trial monitoring, mental health & physical therapy.
20
Mar
2023
Bionest
FDA Finalizes Guidance on Multiple Endpoints in Clinical Trials
Assessing multiple endpoints in clinical trial results can prove challenging, prompting the FDA to provide new guidance for drug sponsors.
7
Nov
2022
Bionest
Down to the Wire: The Race Between Amgen and Mirati for KRAS-Inhibitor Approvals
Who is ahead in the race for KRAS-inhibitor approval? We explore the latest drug development updates for sotorasib and adagrasib.
11
Apr
2022
Bionest
Use of Decentralized Trials Growing, But Barriers to Adoption Remain
Despite their benefits, decentralized clinical trials still face many barriers to widespread adoption. What will it take to overcome them?
28
Oct
2020
Bionest
Time to Embrace Decentralized Clinical Trials
A clearer roadmap for decentralized clinical trials will enable companies to better plan and more quickly advance their adoption of these strategies, which have the potential of benefiting patients and drug developers alike.
21
Oct
2019
Bionest
New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer
Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its early stages, when the disease is easiest to treat, patients are usually asymptomatic. The disease...
2
Sep
2019
Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain
On July 18, Novartis told analysts its Zolgensma launch was “on track.” Despite the gene therapy’s $2.1 million price tag, the company states the launch is “one of the most successful launches from an access standpoint in rare diseases.” Novartis said it had reached coverage deals with more than 20 commercial insurance plans, covering approximately 40%...
12
Aug
2019